Related projects
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Late-stage, therapy-resistant prostate cancer (PCa) remains a difficult-to-treat disease that urgently needs better therapeutics. Advanced PCa cells use glucose (sugar) differently than normal cells, substantially increasing lactic acid secretion into the surrounding environment. This supports cancer growth in numerous important ways, including helping PCa avoiding destruction by the patient’s immune system. One critical protein involved in this process is MCT4, which transports lactic acid out of cells. We previously showed that blocking lactic acid secretion from MCT4 can be an effective therapeutic strategy. Recently we used a unique computer-based drug discovery platform to develop a novel class of chemicals with anti-MCT4 effects. We now propose to upgrade these MCT4 inhibitors into potent therapeutics for testing in clinical trials. We will also use a comprehensive panel of patient-derived PCa models to accurately predict patient responses to therapies, accelerating the development of a new generation of effective MCT4-targeting drugs.
Christopher J Ong
Stephen Yiu Chuen Choi;Jennifer Xiao Jia Niu;Xinpei Ci
LAST Innovations Ltd
Other
Professional, scientific and technical services
University of British Columbia
Accelerate
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Find the perfect opportunity to put your academic skills and knowledge into practice!
Find ProjectsThe strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.